Hemoglobinopathies: Clinical Trials

220 trials for Hemoglobinopathies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

112 completed, 30 recruiting, 28 terminated, 21 active not recruiting. 220 Phase 1, 94 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1220Completed 112, Recruiting 30, Terminated 28, Active not recruiting 21, Unknown 12, Withdrawn 11, Not yet recruiting 5, Enrolling by invitation 1
Phase 294Completed 34, Active not recruiting 16, Recruiting 16, Terminated 13, Unknown 7, Withdrawn 4, Not yet recruiting 3, Enrolling by invitation 1

Follow Hemoglobinopathies: new trials by email Literature Review of Hemoglobinopathies trials Research Report on Hemoglobinopathies

Trials (filtered) newest first · largest first

All 220 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Buprenorphine for the Management of Pain in Children With Sickle Cell Disease
Buprenorphine Buccal Film [Belbuca] - Sickle Cell Disease (SCD), Sickle Cell Disease Vaso-occlusive Crisis
Phase 1Not yet recruitingNatasha Archer252027-01-012026-11-04
Minocycline In Neurocognitive Outcomes - Sickle Cell Disease
Minocycline, Placebo - Sickle Cell Disease, Cognitive Impairment
Phase 1Not yet recruitingUniversity of Cincinnati302026-12-012026-11-03
Feasibility and Acceptability of Amani
Amani - Sickle Cell Disease
Phase 1 / Phase 2Not yet recruitingMassachusetts General Hospital402026-11-012026-08-07
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Sickle Cell Disease
autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein, Sequencing Assay for Variant rs114518452 - Sickle Cell Disease, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Phase 1RecruitingDaniel Bauer52026-08-012026-10-21
Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease
VAS-101 - Sickle Cell Disease, Hemolytic Anemia
Phase 1RecruitingNational Heart, Lung, and Blood Institute (NHLBI)252026-07-312026-10-21
Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
Total Body Irradiation, Alemtuzumab, Abatacept - Sickle Cell Disease, Beta-thalassemia
Phase 1 / Phase 2RecruitingNational Heart, Lung, and Blood Institute (NHLBI)902026-07-082026-10-13
Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
Ruxolitinib - Sickle Cell Disease, Hematopoetic Stem Cell Transplant
Phase 1 / Phase 2RecruitingArkansas Children's Hospital Research Institute242026-06-082026-06-04
STEM CELL MOBILIZATION WITH HIGH-DOSE PLERIXAFOR IN PATIENTS WITH SICKLE CELL DISEASE
Plerixafor Dose Escalation - Sickle Cell Disease
Phase 1 / Phase 2Not yet recruitingHospital Israelita Albert Einstein122026-06-012026-01-14
Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study
hydroxycarbamide - Sickle Cell Disease, Sickle Cell Anemia in Children
Phase 1 / Phase 2RecruitingChildren's Hospital Medical Center, Cincinnati2502026-05-132026-07-16
Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.
DREAM01 drug product, anti-inflammatory therapy - Sickle Cell Disease
Phase 1 / Phase 2RecruitingAssistance Publique - Hôpitaux de Paris152026-02-252026-03-04
A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
DISC-3405 - Sickle Cell Disease
Phase 1RecruitingDisc Medicine, Inc242026-01-062026-11-13
Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease
Pociredir - Sickle Cell Disease
Phase 1TerminatedFulcrum Therapeutics132025-12-132026-06-18
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein, Sequencing Assay for Variant rs114518452 - Sickle Cell Disease, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Phase 1RecruitingDaniel Bauer102025-12-012026-02-03
Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
Extended-Release Methylphenidate - Sickle Cell Disease, Executive Dysfunction
Phase 1RecruitingSt. Jude Children's Research Hospital722025-11-252026-09-09
Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease
CRISPR_SCD001 - Sickle Cell Disease
Phase 1 / Phase 2RecruitingMark Walters, MD92025-08-222026-10-20
A Phase I Study of SNH-119014 in Healthy Volunteers
SNH-119014, Placebo - Hemoglobinopathy
Phase 1RecruitingScinnoHub Pharmaceutical Co., Ltd.962025-06-272025-07-25
A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants
Etavopivat, Moxifloxacin, Placebo - Healthy Volunteers, Sickle Cell Disease
Phase 1CompletedNovo Nordisk A/S332025-06-092026-01-02
131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)
131I-apamistmab, Sirolimus, Campath - Sickling Disorder Due to Hemoglobin S
Phase 1RecruitingColumbia University242025-04-282026-06-10
ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia
ALS20 - Beta-Thalassemia
Phase 1 / Phase 2Active not recruitingChildren's Hospital of Philadelphia122025-04-142026-10-29
Cannabidiol in Sickle Cell Disease
Cannabidiol, Placebo - Sickle Cell Disease
Phase 1 / Phase 2RecruitingIcahn School of Medicine at Mount Sinai522025-04-032025-06-25

Showing 20 of 220. Sign in to see all of them.

Narrower conditions

Anemia, Sickle Cell (182)  ·  beta-Thalassemia (35)  ·  Thalassemia (33)  ·  Anemia (10)  ·  Anemia, Diamond-Blackfan (10)  ·  Vaso-Occlusive Crises (9)  ·  Hematologic Diseases (8)  ·  Anemia, Aplastic (7)  ·  Genetic Diseases, Inborn (7)  ·  Anemia, Hemolytic (6)  ·  Bone Marrow Failure Disorders (6)  ·  Hemoglobin SC Disease (6)  ·  Hypertension, Pulmonary (6)  ·  Sickle Cell Trait (6)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (220)  ·  Hemic and Lymphatic Diseases (220)  ·  Genetic Diseases, Inborn (213)  ·  Anemia, Hemolytic, Congenital (212)  ·  Hematologic Diseases (212)  ·  Anemia, Hemolytic (210)  ·  Anemia (207)  ·  Thalassemia (31)  ·  Pathological Conditions, Signs and Symptoms (25)  ·  Nutritional and Metabolic Diseases (18)  ·  Immune System Diseases (16)  ·  Pathologic Processes (16)  ·  Metabolic Diseases (15)  ·  Bone Marrow Diseases (14)

Interventions

Hydroxyurea (16)  ·  Alemtuzumab (14)  ·  Sirolimus (13)  ·  fludarabine (9)  ·  Cyclophosphamide (7)  ·  plerixafor (7)  ·  voxelotor (6)  ·  Abatacept (5)  ·  Hematopoietic Stem Cell Transplantation (5)  ·  Mycophenolic Acid (5)  ·  fludarabine phosphate (5)  ·  Busulfan (4)  ·  Melphalan (4)  ·  Stem Cell Transplantation (4)  ·  Tacrolimus (4)

Sponsors

National Heart, Lung, and Blood Institute (NHLBI) (17)  ·  Pfizer (6)  ·  St. Jude Children's Research Hospital (5)  ·  Children's Hospital Medical Center, Cincinnati (4)  ·  City of Hope Medical Center (4)  ·  Emory University (4)  ·  Global Blood Therapeutics (4)  ·  Novo Nordisk A/S (4)  ·  Washington University School of Medicine (4)  ·  Assistance Publique - Hôpitaux de Paris (3)  ·  Bellicum Pharmaceuticals (3)  ·  Children's Hospital Los Angeles (3)  ·  Children's Hospital of Philadelphia (3)  ·  Fulcrum Therapeutics (3)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3)

Countries

United States (163)  ·  China (12)  ·  Canada (9)  ·  United Kingdom (9)  ·  France (8)  ·  Italy (6)  ·  Lebanon (5)  ·  Nigeria (5)  ·  Thailand (4)  ·  Australia (3)  ·  Brazil (3)  ·  Jamaica (3)  ·  Kenya (3)  ·  Netherlands (3)  ·  Spain (3)

Top investigators

John F Tisdale, M.D. (10)  ·  Carla Washington, PhD (3)  ·  Swee Lay Thein, M.D. (3)  ·  A O Dosunmu, M.D. (2)  ·  Abdullah Kutlar, MD (2)  ·  Courtney D Fitzhugh, M.D. (2)  ·  Courtney F Joseph, M.D. (2)  ·  Diane George, MD (2)  ·  Shalini Shenoy, MD (2)

Results publications

PMID 36240296, PMID 42133908, PMID 24916507, PMID 26348869, PMID 26589907, PMID 34175041, PMID 36860093, PMID 36975201, PMID 37254256, PMID 38866240, PMID 40891510, PMID 41871072, PMID 15592491, PMID 16990602, PMID 17536019, PMID 17620452, PMID 18026148, PMID 18439858, PMID 18500373, PMID 18550886, PMID 19840322, PMID 20007560, PMID 20117846, PMID 20644039, PMID 20732454, PMID 20797926, PMID 20936416, PMID 21477202, PMID 21742281, PMID 22875626, PMID 22887019, PMID 23377438, PMID 23416852, PMID 23973010, PMID 24296492, PMID 24988449, PMID 25058217, PMID 25222041, PMID 25701866, PMID 25938131, PMID 26021713, PMID 26275071, PMID 26719803, PMID 27862048, PMID 28096387, PMID 28152086, PMID 28249145, PMID 28331623, PMID 28880867, PMID 28884840

NIH funding

2014 (3), 1RC2HL101367-01 (1), 1ZIAHL006149-01 (1), 2017 (1), 2019 (1), 2023 (1), 2025 (1), K23HL133446 (1), K23HL146904 (1), K24AT009893 (1), P20GM109021 (1), P30CA033572 (1), R01DK055463 (1), R01HL154629 (1), R01NS045948 (1)